LV10907B - Peg/protein derivatives of interferon - Google Patents

Peg/protein derivatives of interferon Download PDF

Info

Publication number: LV10907B
Authority: LV; Latvia
Prior art keywords: interferon; conjugate; compound; peg; lower alkyl
Prior art date: 1992-08-26

Application number

LVP-93-1040A

Other languages

English (en)

Latvian (lv)

Other versions

LV10907A (lv

Inventor

Karasiewicz Robert

Nalin Carlo

Rosen Perry

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-08-26

Filing date

1993-08-25

Publication date

1996-04-20

1993-08-25 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

1995-12-20 Publication of LV10907A publication Critical patent/LV10907A/xx

1996-04-20 Publication of LV10907B publication Critical patent/LV10907B/en

Links

229940079322 interferon Drugs 0.000 title claims abstract description 97
102000014150 Interferons Human genes 0.000 title claims abstract description 88
108010050904 Interferons Proteins 0.000 title claims abstract description 88
102000004169 proteins and genes Human genes 0.000 title description 55
108090000623 proteins and genes Proteins 0.000 title description 55
229920001223 polyethylene glycol Polymers 0.000 claims abstract description 44
239000002202 Polyethylene glycol Substances 0.000 claims abstract description 40
150000001875 compounds Chemical class 0.000 claims description 45
125000000217 alkyl group Chemical group 0.000 claims description 30
238000000034 method Methods 0.000 claims description 29
125000003277 amino group Chemical group 0.000 claims description 28
229920000642 polymer Polymers 0.000 claims description 15
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 14
229910052739 hydrogen Inorganic materials 0.000 claims description 6
239000001257 hydrogen Substances 0.000 claims description 5
239000008194 pharmaceutical composition Substances 0.000 claims description 5
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
230000002265 prevention Effects 0.000 claims description 3
230000021615 conjugation Effects 0.000 claims description 2
239000011541 reaction mixture Substances 0.000 claims description 2
150000003839 salts Chemical class 0.000 claims description 2
239000000126 substance Substances 0.000 claims description 2
238000011282 treatment Methods 0.000 claims 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
201000010099 disease Diseases 0.000 claims 2
239000003814 drug Substances 0.000 claims 2
208000035473 Communicable disease Diseases 0.000 claims 1
206010028980 Neoplasm Diseases 0.000 claims 1
229920000547 conjugated polymer Polymers 0.000 claims 1
230000006806 disease prevention Effects 0.000 claims 1
230000002519 immonomodulatory effect Effects 0.000 claims 1
238000004519 manufacturing process Methods 0.000 claims 1
238000011321 prophylaxis Methods 0.000 claims 1
229940124597 therapeutic agent Drugs 0.000 claims 1
238000002360 preparation method Methods 0.000 abstract description 8
150000002334 glycols Chemical class 0.000 abstract description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 2
238000006243 chemical reaction Methods 0.000 description 17
239000000243 solution Substances 0.000 description 13
239000000203 mixture Substances 0.000 description 12
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
230000004071 biological effect Effects 0.000 description 9
IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 8
230000000694 effects Effects 0.000 description 8
238000012986 modification Methods 0.000 description 8
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 8
239000002904 solvent Substances 0.000 description 8
230000004048 modification Effects 0.000 description 7
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
239000007795 chemical reaction product Substances 0.000 description 6
-1 2-pyridinyloxy Chemical group 0.000 description 5
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 5
229910052921 ammonium sulfate Inorganic materials 0.000 description 5
235000011130 ammonium sulphate Nutrition 0.000 description 5
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 5
238000009833 condensation Methods 0.000 description 5
230000005494 condensation Effects 0.000 description 5
GCSAXWHQFYOIFE-UHFFFAOYSA-N dipyridin-2-yl carbonate Chemical compound C=1C=CC=NC=1OC(=O)OC1=CC=CC=N1 GCSAXWHQFYOIFE-UHFFFAOYSA-N 0.000 description 5
239000000047 product Substances 0.000 description 5
239000011780 sodium chloride Substances 0.000 description 5
VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 4
239000005695 Ammonium acetate Substances 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical group CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 4
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 4
229940043376 ammonium acetate Drugs 0.000 description 4
235000019257 ammonium acetate Nutrition 0.000 description 4
238000007796 conventional method Methods 0.000 description 4
WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 4
239000001632 sodium acetate Substances 0.000 description 4
235000017281 sodium acetate Nutrition 0.000 description 4
238000002835 absorbance Methods 0.000 description 3
239000003153 chemical reaction reagent Substances 0.000 description 3
238000004587 chromatography analysis Methods 0.000 description 3
238000003776 cleavage reaction Methods 0.000 description 3
230000001268 conjugating effect Effects 0.000 description 3
125000003827 glycol group Chemical group 0.000 description 3
238000004128 high performance liquid chromatography Methods 0.000 description 3
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
229940047124 interferons Drugs 0.000 description 3
125000005647 linker group Chemical group 0.000 description 3
230000007017 scission Effects 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
239000001488 sodium phosphate Substances 0.000 description 3
229910000162 sodium phosphate Inorganic materials 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 3
PVVTWNMXEHROIA-UHFFFAOYSA-N 2-(3-hydroxypropyl)-1h-quinazolin-4-one Chemical compound C1=CC=C2NC(CCCO)=NC(=O)C2=C1 PVVTWNMXEHROIA-UHFFFAOYSA-N 0.000 description 2
229960000549 4-dimethylaminophenol Drugs 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 2
239000004471 Glycine Substances 0.000 description 2
102000006992 Interferon-alpha Human genes 0.000 description 2
108010047761 Interferon-alpha Proteins 0.000 description 2
SEQKRHFRPICQDD-UHFFFAOYSA-N N-tris(hydroxymethyl)methylglycine Chemical compound OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 description 2
239000012506 Sephacryl® Substances 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
230000000840 anti-viral effect Effects 0.000 description 2
239000012736 aqueous medium Substances 0.000 description 2
238000003556 assay Methods 0.000 description 2
239000000872 buffer Substances 0.000 description 2
125000004432 carbon atom Chemical group C* 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
238000001502 gel electrophoresis Methods 0.000 description 2
230000003301 hydrolyzing effect Effects 0.000 description 2
230000002209 hydrophobic effect Effects 0.000 description 2
230000002163 immunogen Effects 0.000 description 2
238000011534 incubation Methods 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
VNKYTQGIUYNRMY-UHFFFAOYSA-N methoxypropane Chemical compound CCCOC VNKYTQGIUYNRMY-UHFFFAOYSA-N 0.000 description 2
ZNNZYHKDIALBAK-UHFFFAOYSA-M potassium thiocyanate Chemical compound [K+].[S-]C#N ZNNZYHKDIALBAK-UHFFFAOYSA-M 0.000 description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 2
125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 2
UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical compound OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 description 2
239000011347 resin Substances 0.000 description 2
229920005989 resin Polymers 0.000 description 2
238000000926 separation method Methods 0.000 description 2
239000007787 solid Substances 0.000 description 2
JECYNCQXXKQDJN-UHFFFAOYSA-N 2-(2-methylhexan-2-yloxymethyl)oxirane Chemical compound CCCCC(C)(C)OCC1CO1 JECYNCQXXKQDJN-UHFFFAOYSA-N 0.000 description 1
239000004215 Carbon black (E152) Substances 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108091006006 PEGylated Proteins Proteins 0.000 description 1
108010081690 Pertussis Toxin Proteins 0.000 description 1
YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
UZMAPBJVXOGOFT-UHFFFAOYSA-N Syringetin Natural products COC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UZMAPBJVXOGOFT-UHFFFAOYSA-N 0.000 description 1
239000007997 Tricine buffer Substances 0.000 description 1
VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
239000012062 aqueous buffer Substances 0.000 description 1
239000011324 bead Substances 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
230000008033 biological extinction Effects 0.000 description 1
AFFYTLSODCIHIH-UHFFFAOYSA-N bis(3-methylpyridin-2-yl) carbonate Chemical compound CC1=CC=CN=C1OC(=O)OC1=NC=CC=C1C AFFYTLSODCIHIH-UHFFFAOYSA-N 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000012876 carrier material Substances 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
150000008280 chlorinated hydrocarbons Chemical class 0.000 description 1
238000007398 colorimetric assay Methods 0.000 description 1
238000006482 condensation reaction Methods 0.000 description 1
KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
238000001641 gel filtration chromatography Methods 0.000 description 1
238000002523 gelfiltration Methods 0.000 description 1
239000011521 glass Substances 0.000 description 1
150000004820 halides Chemical class 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
150000002431 hydrogen Chemical class 0.000 description 1
125000004356 hydroxy functional group Chemical group O* 0.000 description 1
230000028993 immune response Effects 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
230000003993 interaction Effects 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
239000000463 material Substances 0.000 description 1
238000006011 modification reaction Methods 0.000 description 1
239000002808 molecular sieve Substances 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
230000006320 pegylation Effects 0.000 description 1
238000003359 percent control normalization Methods 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
AHWALFGBDFAJAI-UHFFFAOYSA-N phenyl carbonochloridate Chemical class ClC(=O)OC1=CC=CC=C1 AHWALFGBDFAJAI-UHFFFAOYSA-N 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
229920000151 polyglycol Polymers 0.000 description 1
239000010695 polyglycol Substances 0.000 description 1
229940116357 potassium thiocyanate Drugs 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
230000008569 process Effects 0.000 description 1
125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
239000012460 protein solution Substances 0.000 description 1
230000035484 reaction time Effects 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
238000001542 size-exclusion chromatography Methods 0.000 description 1
URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
230000003381 solubilizing effect Effects 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000000725 suspension Substances 0.000 description 1
238000005406 washing Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/96—Esters of carbonic or haloformic acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Pharmacology & Pharmacy (AREA)
Molecular Biology (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Biophysics (AREA)
Bioinformatics & Cheminformatics (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Toxicology (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

LVP-93-1040A 1992-08-26 1993-08-25 Peg/protein derivatives of interferon LV10907B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US07/935,770 US5382657A (en)	1992-08-26	1992-08-26	Peg-interferon conjugates

Publications (2)

Publication Number	Publication Date
LV10907A LV10907A (lv)	1995-12-20
LV10907B true LV10907B (en)	1996-04-20

Family

ID=25467637

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LVP-93-1040A LV10907B (en)	1992-08-26	1993-08-25	Peg/protein derivatives of interferon

Country Status (37)

Country	Link
US (1)	US5382657A (sk)
EP (1)	EP0593868B1 (sk)
JP (1)	JP2859105B2 (sk)
KR (1)	KR100295520B1 (sk)
CN (3)	CN1183112C (sk)
AT (1)	ATE165102T1 (sk)
AU (1)	AU668742B2 (sk)
BG (1)	BG98067A (sk)
BR (1)	BR9303469A (sk)
CA (1)	CA2103829C (sk)
CZ (1)	CZ169393A3 (sk)
DE (1)	DE69317979T2 (sk)
DK (1)	DK0593868T3 (sk)
EE (1)	EE9400151A (sk)
ES (1)	ES2116376T3 (sk)
FI (1)	FI109765B (sk)
HR (1)	HRP931094A2 (sk)
HU (1)	HUT67013A (sk)
IL (1)	IL106750A0 (sk)
IS (1)	IS4067A (sk)
LT (1)	LT3174B (sk)
LV (1)	LV10907B (sk)
MW (1)	MW7693A1 (sk)
MX (1)	MX9305146A (sk)
MY (1)	MY131445A (sk)
NO (1)	NO933028D0 (sk)
NZ (2)	NZ248452A (sk)
OA (1)	OA09850A (sk)
PH (1)	PH30460A (sk)
PL (1)	PL300194A1 (sk)
RO (1)	RO112730B1 (sk)
SI (1)	SI9300423A (sk)
SK (1)	SK89893A3 (sk)
UY (1)	UY23635A1 (sk)
YU (1)	YU56693A (sk)
ZA (1)	ZA936098B (sk)
ZW (1)	ZW11193A1 (sk)

Families Citing this family (289)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE68925966T2 (de) *	1988-12-22	1996-08-29	Kirin Amgen Inc	Chemisch modifizierte granulocytenkolonie erregender faktor
ATE289350T1 (de) *	1989-04-21	2005-03-15	Amgen Inc	Tnf-rezeptor, tnf bindende proteine und dafür kodierende dnas
US7264944B1 (en) *	1989-04-21	2007-09-04	Amgen Inc.	TNF receptors, TNF binding proteins and DNAs coding for them
US6143866A (en) *	1989-07-18	2000-11-07	Amgen, Inc.	Tumor necrosis factor (TNF) inhibitor and method for obtaining the same
IL95031A (en)	1989-07-18	2007-03-08	Amgen Inc	A method of producing a recombinant human necrotic factor absorber
US6552170B1 (en)	1990-04-06	2003-04-22	Amgen Inc.	PEGylation reagents and compounds formed therewith
US5595732A (en) *	1991-03-25	1997-01-21	Hoffmann-La Roche Inc.	Polyethylene-protein conjugates
US5880131A (en) *	1993-10-20	1999-03-09	Enzon, Inc.	High molecular weight polymer-based prodrugs
US5919455A (en) *	1993-10-27	1999-07-06	Enzon, Inc.	Non-antigenic branched polymer conjugates
US5951974A (en) *	1993-11-10	1999-09-14	Enzon, Inc.	Interferon polymer conjugates
US5711944A (en) *	1993-11-10	1998-01-27	Enzon, Inc.	Interferon polymer conjugates
ES2159630T3 (es) *	1994-02-08	2001-10-16	Amgen Inc	Sistema de administracion por via oral de proteinas g-csf quimicamente modificadas.
US5730990A (en) *	1994-06-24	1998-03-24	Enzon, Inc.	Non-antigenic amine derived polymers and polymer conjugates
US20030053982A1 (en) *	1994-09-26	2003-03-20	Kinstler Olaf B.	N-terminally chemically modified protein compositions and methods
DE4435087A1 (de) *	1994-09-30	1996-04-04	Deutsches Krebsforsch	Konjugat zur Behandlung von Infektions-, Autoimmun- und Hauterkrankungen
US5824784A (en) *	1994-10-12	1998-10-20	Amgen Inc.	N-terminally chemically modified protein compositions and methods
US5738846A (en) *	1994-11-10	1998-04-14	Enzon, Inc.	Interferon polymer conjugates and process for preparing the same
TW426523B (en) *	1995-04-06	2001-03-21	Hoffmann La Roche	Interferon solution
DE19514087A1 (de) *	1995-04-13	1996-10-17	Deutsches Krebsforsch	Konjugat aus einem Wirkstoff, einem Polyether und ggfs. einem nicht als körperfremd angesehenen, nativen Protein
DK0858343T3 (da)	1995-11-02	2004-05-10	Schering Corp	Kontinuerlig lavdosis cytokininfusionsterapi
US5908621A (en) *	1995-11-02	1999-06-01	Schering Corporation	Polyethylene glycol modified interferon therapy
TW517067B (en) *	1996-05-31	2003-01-11	Hoffmann La Roche	Interferon conjugates
TW555765B (en) *	1996-07-09	2003-10-01	Amgen Inc	Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
US6753165B1 (en) *	1999-01-14	2004-06-22	Bolder Biotechnology, Inc.	Methods for making proteins containing free cysteine residues
US7495087B2 (en)	1997-07-14	2009-02-24	Bolder Biotechnology, Inc.	Cysteine muteins in the C-D loop of human interleukin-11
CN1269805A (zh) *	1997-07-14	2000-10-11	博尔德生物技术公司	生长激素和相关蛋白的衍生物
US7270809B2 (en) *	1997-07-14	2007-09-18	Bolder Biotechnology, Inc.	Cysteine variants of alpha interferon-2
US20080076706A1 (en)	1997-07-14	2008-03-27	Bolder Biotechnology, Inc.	Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
WO1999013894A2 (en) *	1997-09-18	1999-03-25	F. Hoffmann-La Roche Ag	Use of ifn-alpha and amantadine for the treatment of chronic hepatitis c
US6180095B1 (en) *	1997-12-17	2001-01-30	Enzon, Inc.	Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
JP4465109B2 (ja)	1997-12-17	2010-05-19	エンゾンファーマシューティカルズ，インコーポレーテッド	アミノ及びヒドロキシル含有生物活性剤のポリマープロドラッグ
US5981709A (en) *	1997-12-19	1999-11-09	Enzon, Inc.	α-interferon-polymer-conjugates having enhanced biological activity and methods of preparing the same
US5985263A (en) *	1997-12-19	1999-11-16	Enzon, Inc.	Substantially pure histidine-linked protein polymer conjugates
FR2774687B1 (fr) *	1998-02-06	2002-03-22	Inst Nat Sante Rech Med	Lipopeptides contenant un fragment de l'interferon gamma, et leur utilisation dans des compositions pharmaceutiques
US6180096B1 (en)	1998-03-26	2001-01-30	Schering Corporation	Formulations for protection of peg-interferon alpha conjugates
ATE297761T1 (de) *	1998-03-26	2005-07-15	Schering Corp	Zubereitungen zur stabilisierung von peg- interferon alpha konjugaten
DK1075281T3 (da) *	1998-04-28	2005-01-03	Applied Research Systems	Polyol-IFN-beta-konjugater
CZ300540B6 (cs)	1998-05-15	2009-06-10	Schering Corporation	Farmaceutický prostredek obsahující ribavirin v kombinaci s interferonem alfa pro lécbu pacientu s chronickou infekcí hepatitidy C genotypu 1
DE69942578D1 (de)	1998-05-22	2010-08-26	Univ R	Bifunktionelle moleküle sowie darauf basierende therapien.
ITMI981148A1 (it) *	1998-05-22	1999-11-22	Therapicon Srl	Utilizzo di lisozima c modificato per preparare composizioni medicinali per il trattamento di alcune gravi malattie
JP3839667B2 (ja) *	1998-06-08	2006-11-01	エフ．ホフマン−ラロシュアーゲー	慢性Ｃ型肝炎の処置のためのＰｅｇ−ＩＮＦ−アルファ及びリバビリンの使用
AU773542B2 (en) *	1998-06-16	2004-05-27	Board Of Regents Of The University Of Oklahoma, The	Glycosulfopeptides and methods of synthesis and use thereof
US7223845B2 (en)	1998-06-16	2007-05-29	The Board Of Regents Of The University Of Oklahoma	Synthetic glycosulfopeptides and methods of synthesis thereof
US20030143662A1 (en) *	1998-06-16	2003-07-31	Cummings Richard D.	Glycosulfopeptide inhibitors of leukocyte rolling and methods of use thereof
CN1329082C (zh)	1998-10-16	2007-08-01	拜奥根Idec马萨诸塞公司	干扰素－β－1a的聚合物缀合物及其使用
PL200586B1 (pl)	1998-10-16	2009-01-30	Biogen Idec Inc	Polipeptydy zawierające mutanty interferonu-beta-1a, kodujące je cząsteczki kwasów nukleinowych, komórki gospodarza transformowane tymi cząsteczkami, sposób wytwarzania polipeptydów, zawierające je kompozycje farmaceutyczne i zastosowania polipeptydów
US6660843B1 (en) *	1998-10-23	2003-12-09	Amgen Inc.	Modified peptides as therapeutic agents
CA2359345A1 (en)	1999-01-14	2000-07-20	Bolder Biotechnology, Inc.	Methods for making proteins containing free cysteine residues
US8288126B2 (en)	1999-01-14	2012-10-16	Bolder Biotechnology, Inc.	Methods for making proteins containing free cysteine residues
JP2002540065A (ja) *	1999-01-29	2002-11-26	アムジェンインコーポレーテッド	Ｇｃｓｆコンジュゲート
US6362162B1 (en)	1999-04-08	2002-03-26	Schering Corporation	CML Therapy
US6605273B2 (en)	1999-04-08	2003-08-12	Schering Corporation	Renal cell carcinoma treatment
EP2025344B1 (en)	1999-04-08	2011-01-26	Schering Corporation	Melanoma Therapy
US6923966B2 (en)	1999-04-08	2005-08-02	Schering Corporation	Melanoma therapy
JO2291B1 (en)	1999-07-02	2005-09-12	اف . هوفمان لاروش ايه جي	Erythropoietin derivatives
EP2241623A3 (en)	1999-07-07	2010-12-01	ZymoGenetics, Inc.	Monoclonal antibody against a human cytokine receptor
AU4934299A (en) *	1999-07-15	2001-02-05	Kuhnil Pharm. Co., Ltd.	Novel water soluble-cyclosporine conjugated compounds
US6531122B1 (en) *	1999-08-27	2003-03-11	Maxygen Aps	Interferon-β variants and conjugates
US7144574B2 (en) *	1999-08-27	2006-12-05	Maxygen Aps	Interferon β variants and conjugates
US7431921B2 (en) *	2000-04-14	2008-10-07	Maxygen Aps	Interferon beta-like molecules
WO2001026677A1 (fr)	1999-10-12	2001-04-19	Santen Pharmaceutical Co., Ltd.	Complexe a base d'interferon et son utilisation en medecine
CN1309423C (zh)	1999-11-12	2007-04-11	马克西根控股公司	干扰素γ偶联物
EP1231943A1 (en) *	1999-11-12	2002-08-21	Maxygen Holdings Ltd	Interferon gamma conjugates
US6887842B1 (en)	1999-11-19	2005-05-03	The Board Of Trustees Of The Leland Stanford Junior University	Modulating a pharmacokinetic property of a drug by administering a bifunctional molecule containing the drug
US7220552B1 (en)	1999-11-19	2007-05-22	The Board Of Trustees Of The Leland Stanford Junior University	Bifunctional molecules and their use in the disruption of protein-protein interactions
US7498025B1 (en)	1999-11-19	2009-03-03	The Board Of Trustees Of The Leland Stanford Junior University	Targeted bifunctional molecules and therapies based thereon
ATE458814T1 (de)	1999-12-03	2010-03-15	Zymogenetics Inc	Menschliches zytokinrezeptor
DE60139110D1 (de)	2000-01-10	2009-08-13	Maxygen Holdings Ltd	G-csf konjugate
MXPA02007172A (es) *	2000-01-24	2002-12-13	Schering Corp	Combinacion de temozolomida y alfa interferon pegilado para tratamiento de cancer.
EP1908477A3 (en) *	2000-01-24	2008-06-11	Schering Corporation	Combination of temozolomide and pegylated interferon-alpha for treating cancer
DK1257295T3 (da)	2000-02-11	2009-08-10	Bayer Healthcare Llc	Faktor VII eller VIIA-lignende molekyler
KR100353392B1 (ko) *	2000-03-13	2002-09-18	선바이오(주)	높은 생체 활성도를 갖는 생체 활성 단백질과 ｐｅｇ의결합체 제조방법
US6756037B2 (en)	2000-03-31	2004-06-29	Enzon, Inc.	Polymer conjugates of biologically active agents and extension moieties for facilitating conjugation of biologically active agents to polymeric terminal groups
US6777387B2 (en)	2000-03-31	2004-08-17	Enzon Pharmaceuticals, Inc.	Terminally-branched polymeric linkers containing extension moieties and polymeric conjugates containing the same
ATE421535T1 (de) *	2000-10-16	2009-02-15	Chugai Pharmaceutical Co Ltd	Peg-modifiziertes erythropoietin
US20020169290A1 (en) *	2000-11-02	2002-11-14	Claus Bornaes	New multimeric interferon beta polypeptides
US20030092164A1 (en)	2000-11-07	2003-05-15	Gross Jane A.	Human tumor necrosis factor receptor
JP2004533997A (ja)	2001-02-20	2004-11-11	ザイモジェネティクス，インコーポレイティド	Ｂｃｍａ及びｔａｃｉの両者を結合する抗体
DK1362053T3 (da) *	2001-02-20	2008-03-10	Enzon Inc	Terminalt forgrenede polymere linkere og polymere konjugater indeholdende disse
EP2080771A3 (en)	2001-02-27	2010-01-06	Maxygen Aps	New interferon beta-like molecules
CA2439636A1 (en)	2001-03-02	2002-09-12	Zymogenetics, Inc.	Mouse cytokine receptor
US7038015B2 (en) *	2001-04-06	2006-05-02	Maxygen Holdings, Ltd.	Interferon gamma polypeptide variants
US6958388B2 (en)	2001-04-06	2005-10-25	Maxygen, Aps	Interferon gamma polypeptide variants
WO2002083166A1 (fr) *	2001-04-10	2002-10-24	Santen Pharmaceutical Co., Ltd.	Complexes de polymeres d'interferons et leur utilisation medicinale
JP2004535182A (ja)	2001-05-24	2004-11-25	ザイモジェネティクス，インコーポレイティド	Ｔａｃｉ−免疫グロブリン融合タンパク質
JP4142569B2 (ja) *	2001-06-22	2008-09-03	協和醗酵工業株式会社	軟膏剤
MD2053C2 (ro) *	2001-07-10	2003-07-31	Национальный Научно-Практический Центр Превентивной Медицины Министерства Здравоохранения Республики Молдова	Remediu cu acţiune interferonogenă
CA2457876C (en)	2001-08-22	2011-10-11	Bioartificial Gel Technologies Inc.	Process for the preparation of activated polyethylene glycols
AU2002346686A1 (en) *	2001-12-07	2003-06-23	Intermune, Inc.	Compositions and method for treating hepatitis virus infection
KR100888371B1 (ko)	2002-01-17	2009-03-13	동아제약주식회사	가지 달린 고분자 유도체와 인터페론 결합체를 포함하는 항바이러스제
EP3669887A1 (en) *	2002-01-18	2020-06-24	Biogen MA Inc.	Polyalkylene polymer compounds and uses thereof
ES2291620T3 (es) *	2002-03-13	2008-03-01	Beijing Jiankai Technology Co., Ltd.	Derivado de polimeros hidrfilicos con rama tipo y y metodo de preparacion de compuesto metodo que comprende el compuesto anterior.
AU2003223482A1 (en) *	2002-04-11	2003-10-27	Zymogenetics, Inc.	Use of interleukin-24 to treat ovarian cancer
CA2482368A1 (en)	2002-04-19	2003-10-30	Zymogenetics, Inc.	Cytokine receptor
WO2004000366A1 (en)	2002-06-21	2003-12-31	Novo Nordisk Health Care Ag	Pegylated factor vii glycoforms
US7524931B2 (en) *	2002-07-03	2009-04-28	Maxygen Holdings Ltd.	Full-length interferon gamma polypeptide variants
RU2318004C2 (ru) *	2002-07-24	2008-02-27	Ф.Хоффманн-Ля Рош Аг	Добавки в виде полиалкиленгликолевой кислоты
JP2006510589A (ja) *	2002-09-05	2006-03-30	ザジェネラルホスピタルコーポレーション	アシアロインターフェロンおよび肝臓癌の治療
US20040136955A1 (en) *	2002-09-05	2004-07-15	Barker Nicholas P	Modified asialo-interferons and uses thereof
DE60313786T2 (de) *	2002-09-27	2008-01-24	F. Hoffmann-La Roche Ag	Poly(ethylen glykol)-konjugate von insulinähnlichem wachstumfaktor bindenden protein-4
US20040175359A1 (en) *	2002-11-12	2004-09-09	Desjarlais John Rudolph	Novel proteins with antiviral, antineoplastic, and/or immunomodulatory activity
US7314613B2 (en) *	2002-11-18	2008-01-01	Maxygen, Inc.	Interferon-alpha polypeptides and conjugates
BR0317752A (pt) *	2002-12-26	2005-11-22	Mountain View Pharmaceuticals	Conjugados poliméricos de citocinas, quimiocinas, fatores do crescimento, hormÈnios polipeptìdicos e seus antagonistas com atividade de ligação a receptores conservada
PT1667708E (pt) *	2002-12-26	2012-09-14	Mountain View Pharmaceuticals	Conjugados de interferão-beta-1b e polietileno glicol apresentando uma potência biológica in vitro aumentada
WO2004060406A2 (en) *	2002-12-31	2004-07-22	Nektar Therapeutics Al, Corporation	Polymeric reagents comprising a ketone or a related functional group
MXPA05008785A (es) *	2003-02-19	2005-10-18	Pharmacia Corp	Esteres de polietilen glicol activados.
CN1997666A (zh) *	2003-02-26	2007-07-11	印特缪恩股份有限公司	聚乙二醇修饰的干扰素组合物及其使用方法
US20070077225A1 (en) *	2003-02-28	2007-04-05	Blatt Lawrence M	Continuous delivery methods for treating hepatitis virus infection
CA2458085A1 (en)	2003-03-21	2004-09-21	F. Hoffmann-La Roche Ag	Transcriptional activity assay
WO2005016241A2 (en)	2003-05-16	2005-02-24	Intermune, Inc.	Synthetic chemokine receptor ligands and methods of use thereof
PL2251353T3 (pl)	2003-08-07	2013-08-30	Zymogenetics Inc	Homogenne preparaty IL-29
GB0320638D0 (en)	2003-09-03	2003-10-01	Novartis Ag	Organic compounds
CN1867581B (zh)	2003-10-10	2012-02-01	诺沃挪第克公司	Il-21衍生物
OA13315A (en)	2003-10-14	2007-04-13	Intermune Inc	Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of HCV replication.
ES2428358T3 (es)	2003-10-17	2013-11-07	Novo Nordisk A/S	Terapia de combinación
WO2005042563A2 (en) *	2003-10-22	2005-05-12	Akzo Nobel N.V.	Process for incrasing protein pegylation reaction yields by diafiltration ultrafiltration
WO2005040758A2 (en) *	2003-10-24	2005-05-06	Intermune, Inc.	Use of pirfenidone in therapeutic regimens
WO2005062949A2 (en) *	2003-12-23	2005-07-14	Intermune, Inc.	Method for treating hepatitis virus infection
GB0500020D0 (en)	2005-01-04	2005-02-09	Novartis Ag	Organic compounds
CA2553034A1 (en) *	2004-02-02	2005-08-18	Ambrx, Inc.	Modified human interferon polypeptides and their uses
US7351787B2 (en) *	2004-03-05	2008-04-01	Bioartificial Gel Technologies, Inc.	Process for the preparation of activated polyethylene glycols
WO2005113592A2 (en)	2004-05-19	2005-12-01	Maxygen, Inc.	Interferon-alpha polypeptides and conjugates
WO2005123113A2 (en) *	2004-06-14	2005-12-29	Intermune, Inc.	Interferon compositions and methods of use thereof
CA2568952C (en) *	2004-06-18	2019-05-21	Ambrx, Inc.	Novel antigen-binding polypeptides and their uses
AU2005327906B2 (en) *	2004-07-21	2010-05-13	Ambrx, Inc.	Biosynthetic polypeptides utilizing non-naturally encoded amino acids
CN101829318B (zh)	2004-07-29	2012-07-04	津莫吉尼蒂克斯有限责任公司	Il-28和il-29治疗癌症和自身免疫性疾病的用途
US7632491B2 (en)	2004-08-12	2009-12-15	Schering Corporation	Stable pegylated interferon formulation
EP2301963A1 (en)	2004-09-23	2011-03-30	Vasgene Therapeutics, Inc.	Polypeptide compounds for inhibiting angiogenesis and tumor growth
US7736872B2 (en) *	2004-12-22	2010-06-15	Ambrx, Inc.	Compositions of aminoacyl-TRNA synthetase and uses thereof
KR101224781B1 (ko) *	2004-12-22	2013-01-21	암브룩스, 인코포레이티드	비천연적으로 코딩된 아미노산을 포함하는 인간 성장호르몬의 조제물
JP2008525032A (ja)	2004-12-22	2008-07-17	アンブレツクス・インコーポレイテツド	組換えヒト成長ホルモンを発現及び精製するための方法
EP1836314B1 (en) *	2004-12-22	2012-01-25	Ambrx, Inc.	Modified human growth hormone
JP2008532931A (ja)	2005-02-08	2008-08-21	ザイモジェネティクス，インコーポレイテッド	抗ｉｌ−２０、抗ｉｌ−２２および抗ｉｌ−２２ｒａ抗体ならびに結合パートナー、ならびに炎症における使用法
ES2609429T3 (es)	2005-05-12	2017-04-20	Zymogenetics, Inc.	Composiciones y métodos para modular respuestas inmunitarias
CN101501068A (zh) *	2005-05-18	2009-08-05	马克西根公司	改进的α-干扰素多肽
EP1893229B1 (en) *	2005-06-03	2011-10-19	Ambrx, Inc.	Improved human interferon molecules and their uses
US20090042790A1 (en) *	2005-06-13	2009-02-12	Nastech Pharmaceutical Company Inc.	Transmucosal delivery of peptide derivatives
BRPI0613142A2 (pt)	2005-06-17	2010-12-21	Novartis Ag	uso de sangliferina em hcv
US8633300B2 (en)	2005-06-17	2014-01-21	Novo Nordisk Healthcare Ag	Selective reduction and derivatization of engineered proteins comprising at least one non-native cysteine
US7695710B2 (en)	2005-06-20	2010-04-13	Pepgen Corporation	Antitumor and antiviral combination therapies using low-toxicity, long-circulating human interferon-alpha analogs
CN101257925A (zh) *	2005-06-20	2008-09-03	派普根公司	人干扰素α类似物和干扰素τ的低毒长循环的嵌合体
ES2436761T3 (es) *	2005-06-29	2014-01-07	Yeda Research And Development Co., Ltd.	Mutantes de interferón alfa 2 (IFN alfa 2) recombinante
US20090148407A1 (en)	2005-07-25	2009-06-11	Intermune, Inc.	Novel Macrocyclic Inhibitors of Hepatitis C Virus Replication
CN103103238B (zh) *	2005-08-18	2016-08-10	Ambrx公司	一种在细胞中制造在特定位置处具有所选氨基酸的抗体或抗体片段多肽的方法
PL1931697T3 (pl)	2005-09-28	2011-03-31	Zymogenetics Inc	Antagoniści interleukiny IL-17A i IL-17F oraz sposoby ich zastosowania
CN101415705B (zh)	2005-10-11	2011-10-26	因特蒙公司	抑制丙型肝炎病毒复制的化合物和方法
US20080171696A1 (en) *	2005-10-21	2008-07-17	Avigenics, Inc.	Pharmacodynamically enhanced therapeutic proteins
US20070092486A1 (en) *	2005-10-21	2007-04-26	Avigenics, Inc.	Glycolated and glycosylated poultry derived therapeutic proteins
JP5508716B2 (ja) *	2005-11-08	2014-06-04	アンブルックス，インコーポレイテッド	非天然アミノ酸、および非天然アミノ酸ポリペプチドを修飾するための促進剤
CN101454461A (zh) *	2005-11-16	2009-06-10	Ambrx公司	包括非天然氨基酸的方法和组合物
DK1968635T3 (en) *	2005-12-14	2014-12-15	Ambrx Inc	Compositions and Methods of, and uses of non-natural amino acids and polypeptides
CA2636914C (en)	2006-01-12	2016-08-09	Kuniaki Yoshioka	Oral composition containing interferon-.alpha.
CN100475270C (zh)	2006-01-20	2009-04-08	清华大学	一种治疗肿瘤的药物及其应用
CN101002945B (zh)	2006-01-20	2012-09-05	清华大学	一种用于肿瘤治疗的新型复合物
NZ571826A (en)	2006-04-11	2012-01-12	Novartis Ag	HCV/HIV inhibitors and their uses
CA2653748A1 (en) *	2006-05-02	2007-11-15	Allozyne, Inc.	Non-natural amino acid substituted polypeptides
US20080096819A1 (en) *	2006-05-02	2008-04-24	Allozyne, Inc.	Amino acid substituted molecules
CN101484576A (zh)	2006-05-24	2009-07-15	诺沃-诺迪斯克保健股份有限公司	具有延长的体内半寿期的因子ix类似物
CN101336110B (zh)	2006-06-01	2011-06-01	程云	预防或治疗肝损伤的肽及其衍生物及其应用
CN1911447B (zh) *	2006-06-30	2010-05-12	复旦大学	转铁蛋白-聚乙二醇-药物分子复合物及其制备药物的用途
EP1886685A1 (en)	2006-08-11	2008-02-13	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition
CA2666814A1 (en) *	2006-08-21	2008-05-29	United Therapeutics Corporation	Combination therapy for treatment of viral infections
WO2008030558A2 (en) *	2006-09-08	2008-03-13	Ambrx, Inc.	Modified human plasma polypeptide or fc scaffolds and their uses
JP5451390B2 (ja) *	2006-09-08	2014-03-26	アンブルックス，インコーポレイテッド	脊椎動物細胞内におけるサプレッサーｔｒｎａの転写
SG174781A1 (en) *	2006-09-08	2011-10-28	Ambrx Inc	Hybrid suppressor trna for vertebrate cells
MX2009005466A (es)	2006-11-22	2009-08-17	Adnexus A Bristol Myers Sqibb	Terapeuticos dirigidos a base de proteinas manipuladas para receptores de tirosina cinasas, incluyendo receptor de factor de crecimiento tipo insulina-i.
CN101219219B (zh) *	2007-01-10	2013-02-13	北京普罗吉生物科技发展有限公司	包含血管抑素或其片段的复合物、其制备方法及应用
WO2008097497A2 (en)	2007-02-02	2008-08-14	Adnexus, A Bristol-Myers Squibb R & D Company	Vegf pathway blockade
ES2385114T3 (es)	2007-03-30	2012-07-18	Ambrx, Inc.	Polipéptidos de FGF-21 modificados y sus usos
NZ580686A (en) *	2007-05-02	2012-11-30	Ambrx Inc	Modified interferon beta polypeptides and their uses
CA2707840A1 (en)	2007-08-20	2009-02-26	Allozyne, Inc.	Amino acid substituted molecules
RU2485134C2 (ru)	2007-09-04	2013-06-20	Биостид Джене Експрешен Тек. Ко., Лтд.	Интерферон альфа 2в, модифицированный полиэтиленгликолем, получение препарата и его применение
DK2196475T3 (da)	2007-09-04	2012-09-17	Biosteed Gene Expression Tech Co Ltd	Interferon alfa 2a, som er modificeret med polyethylenglycol, fremgangsmåde til syntese deraf samt anvendelse deraf
EP2197489B2 (en)	2007-10-04	2020-04-01	ZymoGenetics, Inc.	B7 family member zb7h6 and related compositions and methods
MX2010004327A (es)	2007-10-22	2010-05-13	Schering Corp	Anticuerpos anti-vegf completamente humanos y metodos de uso.
NZ603812A (en)	2007-11-20	2014-06-27	Ambrx Inc	Modified insulin polypeptides and their uses
ES2660036T3 (es)	2007-12-07	2018-03-20	Zymogenetics, Inc.	Moléculas de anticuerpo humanizadas específicas para IL-31
NZ586947A (en)	2008-02-08	2012-11-30	Ambrx Inc	Modified leptin polypeptides and their uses
PT2272875E (pt)	2008-04-03	2014-04-28	Biosteed Gene Expression Tech Co Ltd	Hormona de crescimento modificada com polietilenoglicol de cadeia dupla, método de preparação e aplicação deste
EP2799448A1 (en)	2008-05-22	2014-11-05	Bristol-Myers Squibb Company	Multivalent fibronectin based scaffold domain proteins
US8658766B2 (en)	2008-06-27	2014-02-25	Zymogenetics, Inc.	Soluble hybrid Fcγ receptors and related methods
CN106928339A (zh)	2008-07-23	2017-07-07	Ambrx 公司	经修饰的牛g‑csf多肽和其用途
CN107022020A (zh)	2008-09-26	2017-08-08	Ambrx公司	修饰的动物促红细胞生成素多肽和其用途
BRPI0919031A2 (pt) *	2008-09-26	2014-09-23	Ambrx Inc	Micro-organismos e vacinas dependentes de replicação através do uso de aminoácidos não naturais
EP3025727A1 (en)	2008-10-02	2016-06-01	The J. David Gladstone Institutes	Methods of treating liver disease
CN102448458B (zh)	2009-03-18	2015-07-22	小利兰·斯坦福大学理事会	治疗黄病毒科病毒感染的方法和组合物
US20110182850A1 (en)	2009-04-10	2011-07-28	Trixi Brandl	Organic compounds and their uses
US8512690B2 (en)	2009-04-10	2013-08-20	Novartis Ag	Derivatised proline containing peptide compounds as protease inhibitors
EP3248619A3 (en)	2009-06-04	2018-03-07	Novartis AG	Methods for identification of sites for igg conjugation
EP2459211A1 (en)	2009-07-31	2012-06-06	Medtronic, Inc.	Continuous subcutaneous administration of interferon- to hepatitis c infected patients
EA201200650A1 (ru)	2009-10-30	2012-12-28	Бёрингер Ингельхайм Интернациональ Гмбх	Курсы комбинированного лечения вируса гепатита с, включающие bi201335, интерферон-альфа и рибавирин
EP2805964A1 (en)	2009-12-21	2014-11-26	Ambrx, Inc.	Modified bovine somatotropin polypeptides and their uses
MX2012006980A (es)	2009-12-21	2012-07-17	Ambrx Inc	Polipeptidos de somatotropina porcina modificados y sus usos.
WO2011143274A1 (en)	2010-05-10	2011-11-17	Perseid Therapeutics	Polypeptide inhibitors of vla4
US8362007B1 (en)	2010-05-11	2013-01-29	Demerx, Inc.	Substituted noribogaine
US9394294B2 (en)	2010-05-11	2016-07-19	Demerx, Inc.	Methods and compositions for preparing and purifying noribogaine
US8765737B1 (en)	2010-05-11	2014-07-01	Demerx, Inc.	Methods and compositions for preparing and purifying noribogaine
CN103180339B (zh)	2010-05-26	2016-04-27	百时美施贵宝公司	具有改善的稳定性的基于纤连蛋白的支架蛋白质
CN102711871A (zh)	2010-06-16	2012-10-03	麦德托尼克公司	用于稳定药物递送装置中的药物的阻尼系统
US8741891B1 (en)	2010-06-22	2014-06-03	Demerx, Inc.	N-substituted noribogaine prodrugs
US9586954B2 (en)	2010-06-22	2017-03-07	Demerx, Inc.	N-substituted noribogaine prodrugs
US8802832B2 (en)	2010-06-22	2014-08-12	Demerx, Inc.	Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
US8637648B1 (en)	2010-06-22	2014-01-28	Demerx, Inc.	Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
JP2013529627A (ja)	2010-06-24	2013-07-22	パンメドリミテッド	ヒドロキシクロロキンまたはヒドロキシクロロキンおよび抗ウイルス剤の組合せを使用するｃ型肝炎ウイルス関連疾患の処置
CA2806232A1 (en)	2010-07-23	2012-01-26	Demerx, Inc.	Noribogaine compositions
US9567386B2 (en)	2010-08-17	2017-02-14	Ambrx, Inc.	Therapeutic uses of modified relaxin polypeptides
PT2605789T (pt)	2010-08-17	2019-09-03	Ambrx Inc	Polipeptidos de relaxina modificados e suas utilizações
AR083006A1 (es)	2010-09-23	2013-01-23	Lilly Co Eli	Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas
KR20140035305A (ko)	2010-10-05	2014-03-21	노파르티스 아게	C형 간염 바이러스 감염의 새로운 치료법
WO2012048235A1 (en)	2010-10-08	2012-04-12	Novartis Ag	Vitamin e formulations of sulfamide ns3 inhibitors
BR112013013166A2 (pt)	2010-11-30	2016-09-06	Novartis Ag	tratamentos da infecção pelo vírus da hepatite c
EP2481740B1 (en)	2011-01-26	2015-11-04	DemeRx, Inc.	Methods and compositions for preparing noribogaine from voacangine
WO2012107589A1 (en)	2011-02-11	2012-08-16	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for the treatment and prevention of hcv infections
MX2013011256A (es)	2011-03-31	2013-10-17	Novartis Ag	Alisporivir para el tratamiento de la infeccion por el virus de hepatitis c.
EP3006037A1 (en)	2011-04-01	2016-04-13	Novartis AG	Treatment for infection with hepatitis b virus alone or in combination with hepatitis delta virus and associated liver diseases
AU2012241859A1 (en)	2011-04-13	2013-10-10	Debiopharm International Sa	Treatment of Hepatitis C virus infection with alisporivir
EP2709669A1 (en)	2011-05-17	2014-03-26	Bristol-Myers Squibb Company	Methods for maintaining pegylation of polypeptides
WO2012158493A2 (en)	2011-05-19	2012-11-22	Geysen Hendrik M	Compounds that bind to the erythropoietin receptor
KR20140054009A (ko)	2011-07-01	2014-05-08	바이엘 인텔렉쳐 프로퍼티 게엠베하	릴랙신 융합 폴리펩타이드 및 그의 용도
WO2013011113A1 (en)	2011-07-20	2013-01-24	Inserm (Institut National De La Sante Et De La Recherche Medicale)	Methods for determining treatment response in patients infected with hcv genotype 4
WO2013028233A1 (en) *	2011-08-25	2013-02-28	Nanogen Pharmaceutical Biotechnology	Peg-interferon lambda 1 conjugates
US9617274B1 (en)	2011-08-26	2017-04-11	Demerx, Inc.	Synthetic noribogaine
EP2760461A1 (en)	2011-09-27	2014-08-06	Novartis AG	Alisporivr for treatment of hepatis c virus infection
JP2015504038A (ja)	2011-10-31	2015-02-05	ブリストル−マイヤーズスクイブカンパニーＢｒｉｓｔｏｌ−ＭｙｅｒｓＳｑｕｉｂｂＣｏｍｐａｎｙ	低減した免疫原性を有するフィブロネクチン結合ドメイン
EP2787999B1 (en)	2011-12-06	2019-01-23	The Board of Trustees of The Leland Stanford Junior University	Methods and compositions for treating viral diseases
EP2788003A4 (en)	2011-12-09	2015-05-27	Demerx Inc	PHOSPHATESTER OF NORIBOGAIN
US8877921B2 (en)	2012-01-25	2014-11-04	Demerx, Inc.	Synthetic voacangine
US9150584B2 (en)	2012-01-25	2015-10-06	Demerx, Inc.	Indole and benzofuran fused isoquinuclidene derivatives and processes for preparing them
US8454947B1 (en)	2012-03-01	2013-06-04	Nanogen Pharmaceutical Biotechnology	PEG-interferon lambda 1 conjugates
WO2013137869A1 (en)	2012-03-14	2013-09-19	Boehringer Ingelheim International Gmbh	Combination therapy for treating hcv infection in an hcv-hiv coinfected patient population
WO2013143581A1 (en)	2012-03-28	2013-10-03	Boehringer Ingelheim International Gmbh	Combination therapy for treating hcv infection in specific patient subgenotype sub-population
CN104411332B (zh)	2012-03-30	2018-11-23	索伦托治疗有限公司	与vegfr2结合的全人抗体
US9844582B2 (en)	2012-05-22	2017-12-19	Massachusetts Institute Of Technology	Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents
WO2013174988A1 (en)	2012-05-24	2013-11-28	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for predicting and monitoring treatment response in hcv- and hcv/hiv-infected subjects
CN104736168B (zh)	2012-05-31	2018-09-21	索伦托治疗有限公司	与pd-l1结合的抗原结合蛋白
DK2859017T3 (da)	2012-06-08	2019-05-13	Sutro Biopharma Inc	Antistoffer omfattrende stedsspecifikke ikke-naturlige aminosyrerester, fremgangsmåder til fremstilling heraf og fremgangsmåder til anvendelse heraf
CN109503714A (zh)	2012-06-21	2019-03-22	索伦托治疗有限公司	与c-Met结合的抗原结合蛋白
JP6438391B2 (ja)	2012-06-22	2018-12-12	ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏＴｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ．	Ｃｃｒ２に結合する抗原結合タンパク質
DK2863955T3 (en)	2012-06-26	2017-01-23	Sutro Biopharma Inc	MODIFIED FC PROTEINS, INCLUDING LOCATION-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, CONJUGATES THEREOF, METHODS OF PRODUCING ITS AND PROCEDURES FOR USE THEREOF
EP4074728A1 (en)	2012-08-31	2022-10-19	Sutro Biopharma, Inc.	Modified peptides comprising an azido group
US20140205566A1 (en)	2012-11-30	2014-07-24	Novartis Ag	Cyclic nucleuoside derivatives and uses thereof
CA2896133A1 (en)	2012-12-20	2014-06-26	Demerx, Inc.	Substituted noribogaine
US8940728B2 (en)	2012-12-20	2015-01-27	Demerx, Inc.	Substituted noribogaine
US9045481B2 (en)	2012-12-20	2015-06-02	Demerx, Inc.	Substituted noribogaine
WO2014120891A2 (en)	2013-02-01	2014-08-07	Bristol-Myers Squibb Company	Fibronectin based scaffold proteins
CN111423511B (zh)	2013-05-31	2024-02-23	索伦托药业有限公司	与pd-1结合的抗原结合蛋白
ES2658039T3 (es)	2013-07-10	2018-03-08	Sutro Biopharma, Inc.	Anticuerpos que comprenden múltiples residuos de aminoácidos no naturales sitio-específicos, métodos para su preparación y métodos de uso
EP3055298B1 (en)	2013-10-11	2020-04-29	Sutro Biopharma, Inc.	Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
US11311519B2 (en)	2014-05-01	2022-04-26	Eiger Biopharmaceuticals, Inc.	Treatment of hepatitis delta virus infection
US10076512B2 (en)	2014-05-01	2018-09-18	Eiger Biopharmaceuticals, Inc.	Treatment of hepatitis delta virus infection
US9388239B2 (en)	2014-05-01	2016-07-12	Consejo Nacional De Investigation Cientifica	Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B
CN111265525A (zh)	2014-05-01	2020-06-12	艾格尔峰生物制药有限公司	丁型肝炎病毒感染的治疗
WO2015195673A2 (en)	2014-06-18	2015-12-23	Demerx, Inc.	Halogenated indole and benzofuran derivatives of isoquinuclidene and processes for preparing them
US20170224777A1 (en)	2014-08-12	2017-08-10	Massachusetts Institute Of Technology	Synergistic tumor treatment with il-2, a therapeutic antibody, and a cancer vaccine
AU2015301753B2 (en)	2014-08-12	2021-04-08	Massachusetts Institute Of Technology	Synergistic tumor treatment with IL-2 and integrin-binding-Fc-fusion protein
KR20170067729A (ko)	2014-08-22	2017-06-16	소렌토 쎄라퓨틱스, 인코포레이티드	Cxcr3에 결합하는 항원 결합 단백질
US9987241B2 (en)	2014-09-25	2018-06-05	The Board Of Regents Of The University Of Oklahoma	Enzyme conjugate and prodrug cancer therapy
EP3209316A2 (en)	2014-10-24	2017-08-30	Bristol-Myers Squibb Company	Modified fgf-21 polypeptides and uses thereof
KR102540109B1 (ko) *	2014-11-06	2023-06-02	파마에센시아 코퍼레이션	Peg화된 인터페론의 투약 요법
CN107532146A (zh) *	2015-03-17	2018-01-02	国立大学法人信州大学	通过使用ifn的非贴壁培养制备树突状细胞的方法
EP3285768B1 (en)	2015-04-21	2020-12-30	Eiger Biopharmaceuticals, Inc.	Pharmaceutical compositions comprising lonafarnib and ritonavir
AU2016349685A1 (en)	2015-11-03	2018-03-15	F. Hoffmann-La Roche Ag	Combination therapy of an HBV capsid assembly inhibitor and an interferon
ES2844629T3 (es)	2015-11-04	2021-07-22	Eiger Biopharmaceuticals Inc	Tratamiento de la infección por el virus de la hepatitis delta
AU2017212717B2 (en)	2016-01-29	2023-11-16	Yuhan Corporation	Antigen binding proteins that bind PD-L1
WO2018087345A1 (en)	2016-11-14	2018-05-17	F. Hoffmann-La Roche Ag	COMBINATION THERAPY OF AN HBsAg INHIBITOR, A NUCLEOS(T)IDE ANALOGUE AND AN INTERFERON
US10350266B2 (en)	2017-01-10	2019-07-16	Nodus Therapeutics, Inc.	Method of treating cancer with a multiple integrin binding Fc fusion protein
CA3049656A1 (en)	2017-01-10	2018-07-19	Nodus Therapeutics	Combination tumor treatment with an integrin-binding-fc fusion protein and immune modulator
JP7189399B2 (ja)	2017-01-18	2022-12-14	アンスティチュナショナルドゥラサンテエドゥラルシェルシュメディカル	骨髄増殖性障害を患う患者の処置のための方法及び医薬組成物
US10266578B2 (en)	2017-02-08	2019-04-23	Bristol-Myers Squibb Company	Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
WO2019020593A1 (en)	2017-07-25	2019-01-31	INSERM (Institut National de la Santé et de la Recherche Médicale)	METHODS AND PHARMACEUTICAL COMPOSITIONS FOR MODULATION OF MONOCYTOPOISIS
WO2020032951A1 (en)	2018-08-09	2020-02-13	The Board Of Regents Of The University Of Oklahoma	Antimalarial enzyme conjugates, kits containing same, and methods of producing and using same
US11485781B2 (en)	2017-08-17	2022-11-01	Massachusetts Institute Of Technology	Multiple specificity binders of CXC chemokines
CN116948006A (zh)	2018-09-11	2023-10-27	北京泰德制药股份有限公司	白介素-2多肽偶联物及其用途
WO2020068261A1 (en)	2018-09-28	2020-04-02	Massachusetts Institute Of Technology	Collagen-localized immunomodulatory molecules and methods thereof
US20220009986A1 (en)	2018-10-19	2022-01-13	Ambrx, Inc.	Interleukin-10 polypeptide conjugates, dimers thereof, and their uses
WO2020154032A1 (en)	2019-01-23	2020-07-30	Massachusetts Institute Of Technology	Combination immunotherapy dosing regimen for immune checkpoint blockade
US20220226488A1 (en)	2019-02-12	2022-07-21	Ambrx, Inc.	Compositions containing, methods and uses of antibody-tlr agonist conjugates
CA3139291A1 (en)	2019-07-18	2021-01-21	Jacky Vonderscher	Method for decreasing adverse-effects of interferon
US20210285000A1 (en)	2020-03-05	2021-09-16	Janssen Pharmaceuticals, Inc.	Combination therapy for treating hepatitis b virus infection
CA3174114A1 (en)	2020-03-11	2021-09-16	Ambrx, Inc.	Interleukin-2 polypeptide conjugates and methods of use thereof
WO2021228983A1 (en)	2020-05-13	2021-11-18	INSERM (Institut National de la Santé et de la Recherche Médicale)	A pharmaceutical composition comprising an arsenic compound, an inductor of type-1 ifn and a protein kinase inhibitor for treating cancer
ES2929379T3 (es)	2020-05-20	2022-11-28	Inst Nat Sante Rech Med	Métodos para el tratamiento de infecciones por coronavirus
JP2023531682A (ja)	2020-06-22	2023-07-25	ヤンセンファーマシューティカルズ，インコーポレーテッド	Ｄ型肝炎ウイルス感染の処置のための組成物および方法
TW202227449A (zh)	2020-08-20	2022-07-16	美商Ａｍｂｒｘ公司	抗體－ｔｌｒ促效劑偶聯物、其方法及用途
WO2022043496A2 (en)	2020-08-28	2022-03-03	INSERM (Institut National de la Santé et de la Recherche Médicale)	Use of mait cells as biomarkers and biotargets in covid-19
WO2022079205A1 (en)	2020-10-15	2022-04-21	INSERM (Institut National de la Santé et de la Recherche Médicale)	Use of ifn-alpha polypeptides for the treatment of coronavirus infections
WO2022159414A1 (en)	2021-01-22	2022-07-28	University Of Rochester	Erythropoietin for gastroinfestinal dysfunction
CA3213805A1 (en)	2021-04-03	2022-10-06	Feng Tian	Anti-her2 antibody-drug conjugates and uses thereof
WO2025006676A2 (en)	2023-06-27	2025-01-02	Firecyte Therapeutics, Inc.	Insulin-like growth factor binding protein like 1 (igfbpl1) compositions and methods of use thereof

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2651657A (en) *	1949-05-21	1953-09-08	Standard Oil Dev Co	Synthetic lubricating oil
SE337223B (sk) *	1967-05-23	1971-08-02	Pharmacia Ab
US3619371A (en) *	1967-07-03	1971-11-09	Nat Res Dev	Production of a polymeric matrix having a biologically active substance bound thereto
SE343210B (sk) *	1967-12-20	1972-03-06	Pharmacia Ab
DK132327A (sk) *	1968-07-16
US3632828A (en) *	1968-12-16	1972-01-04	Dow Chemical Co	Polyethylene glycol monomethyl ether carbonates
BE758425A (fr) *	1969-12-02	1971-04-16	Baxter Laboratories Inc	Streptokinase liee chimiquement a une matrice en carbohydrate (
DE2247163A1 (de) *	1972-09-26	1974-03-28	Merck Patent Gmbh	Traegermatrix zur fixierung biologisch wirksamer stoffe und verfahren zu ihrer herstellung
US4179337A (en) *	1973-07-20	1979-12-18	Davis Frank F	Non-immunogenic polypeptides
US4002531A (en) *	1976-01-22	1977-01-11	Pierce Chemical Company	Modifying enzymes with polyethylene glycol and product produced thereby
US4100271A (en) *	1976-02-26	1978-07-11	Cooper Laboratories, Inc.	Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes
GB1578348A (en) *	1976-08-17	1980-11-05	Pharmacia Ab	Products and a method for the therapeutic suppression of reaginic antibodies responsible for common allergic
US4094744A (en) *	1976-11-18	1978-06-13	W. R. Grace & Co.	Water-dispersible protein/polyurethane reaction product
EP0000938B1 (en) *	1977-08-22	1984-10-17	National Research Development Corporation	Macromolecular covalent conjugates, methods for preparing and pharmaceutical compositions containing them
JPS55110105A (en) *	1979-02-19	1980-08-25	Japan Atom Energy Res Inst	Preparation of polymer composition containing physiologically active material
JPS6023084B2 (ja) *	1979-07-11	1985-06-05	味の素株式会社	代用血液
US4640835A (en) *	1981-10-30	1987-02-03	Nippon Chemiphar Company, Ltd.	Plasminogen activator derivatives
DE3380726D1 (en) *	1982-06-24	1989-11-23	Japan Chem Res	Long-acting composition
WO1985003934A1 (en) *	1984-03-06	1985-09-12	Takeda Chemical Industries, Ltd.	Chemically modified protein and process for its preparation
US4486344A (en) *	1983-03-28	1984-12-04	Miles Laboratories, Inc.	Urea-linked immunogens, antibodies, and preparative method
JPS6098988A (ja) *	1983-11-01	1985-06-01	Chemo Sero Therapeut Res Inst	Ｌｐｆ−ｈａの精製法
JPS60127952A (ja)	1983-12-14	1985-07-08	Fanuc Ltd	領域加工方法
US4496689A (en) *	1983-12-27	1985-01-29	Miles Laboratories, Inc.	Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE3572982D1 (en) *	1984-03-06	1989-10-19	Takeda Chemical Industries Ltd	Chemically modified lymphokine and production thereof
GB8430252D0 (en) *	1984-11-30	1985-01-09	Beecham Group Plc	Compounds
US4732863A (en) *	1984-12-31	1988-03-22	University Of New Mexico	PEG-modified antibody with reduced affinity for cell surface Fc receptors
US4917888A (en) *	1985-06-26	1990-04-17	Cetus Corporation	Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US4766106A (en) *	1985-06-26	1988-08-23	Cetus Corporation	Solubilization of proteins for pharmaceutical compositions using polymer conjugation
DE3676670D1 (de) *	1985-06-26	1991-02-07	Cetus Corp	Solubilisierung von proteinen fuer pharmazeutische zusammensetzungen mittels polymerkonjugierung.
US4847079A (en) *	1985-07-29	1989-07-11	Schering Corporation	Biologically stable interferon compositions comprising thimerosal
US5102872A (en) *	1985-09-20	1992-04-07	Cetus Corporation	Controlled-release formulations of interleukin-2
US5100664A (en) *	1985-09-20	1992-03-31	Cetus Corporation	Human IL-2 as a vaccine adjuvant
US4818769A (en) *	1985-09-20	1989-04-04	Cetus Corporation	Method of controlling stress-related disease in livestock by administration of human IL-2
US4791192A (en) *	1986-06-26	1988-12-13	Takeda Chemical Industries, Ltd.	Chemically modified protein with polyethyleneglycol
US4810638A (en) *	1986-07-24	1989-03-07	Miles Inc.	Enzyme-labeled antibody reagent with polyalkyleneglycol linking group
US4894226A (en) *	1986-11-14	1990-01-16	Cetus Corporation	Solubilization of proteins for pharmaceutical compositions using polyproline conjugation
US4851220A (en) *	1986-11-26	1989-07-25	Schering Corporation	Stable oleaginous gel
US4871538A (en) *	1987-07-13	1989-10-03	Schering Corporation	Insoluble copper-alpha interferon complex
DK468388A (da) *	1987-08-21	1989-02-22	Wellcome Found	Kompleks af polyethylenglycol og vaevplasminogen-aktivator, fremgangsmaade til dets fremstilling og farmaceutiske kompositioner indeholdende komplekset
US4847325A (en) *	1988-01-20	1989-07-11	Cetus Corporation	Conjugation of polymer to colony stimulating factor-1
US5199360A (en)	1988-09-27	1993-04-06	Sirkka Koistinen	Table constructions
GB8824591D0 (en) *	1988-10-20	1988-11-23	Royal Free Hosp School Med	Fractionation process
JPH04502011A (ja) *	1988-11-23	1992-04-09	ジェネンテク，インコーポレイテッド	ポリペプチド誘導体
US4902502A (en) *	1989-01-23	1990-02-20	Cetus Corporation	Preparation of a polymer/interleukin-2 conjugate
ATE300519T1 (de) *	1989-04-19	2005-08-15	Enzon Inc	Verfahren zum herstellen von modifizierten polypeptiden die eine polypeptid und ein polyalkylenoxid enthalten
US5122614A (en) *	1989-04-19	1992-06-16	Enzon, Inc.	Active carbonates of polyalkylene oxides for modification of polypeptides
ES2085297T3 (es) *	1989-05-27	1996-06-01	Sumitomo Pharma	Procedimiento para preparar derivados de poli(etilenglicol) y proteina modificada.
JP2978187B2 (ja) *	1989-11-02	1999-11-15	日本ケミカルリサーチ株式会社	修飾スーパーオキサイドディスムターゼの製造法
US5234903A (en) *	1989-11-22	1993-08-10	Enzon, Inc.	Chemically modified hemoglobin as an effective, stable non-immunogenic red blood cell substitute
WO1991008229A1 (de) *	1989-12-01	1991-06-13	Basf Aktiengesellschaft	Hirudinpolyalkylenglykolkonjugate
JPH04202293A (ja) *	1990-11-29	1992-07-23	Tonen Corp	作動油
US5595732A (en) *	1991-03-25	1997-01-21	Hoffmann-La Roche Inc.	Polyethylene-protein conjugates
US5281698A (en) *	1991-07-23	1994-01-25	Cetus Oncology Corporation	Preparation of an activated polymer ester for protein conjugation

1992
- 1992-08-26 US US07/935,770 patent/US5382657A/en not_active Expired - Lifetime
1993
- 1993-08-03 HR HR07/935,770A patent/HRP931094A2/hr not_active Application Discontinuation
- 1993-08-06 SI SI9300423A patent/SI9300423A/sl unknown
- 1993-08-11 CA CA002103829A patent/CA2103829C/en not_active Expired - Lifetime
- 1993-08-13 DK DK93112983T patent/DK0593868T3/da active
- 1993-08-13 DE DE69317979T patent/DE69317979T2/de not_active Expired - Lifetime
- 1993-08-13 ES ES93112983T patent/ES2116376T3/es not_active Expired - Lifetime
- 1993-08-13 AT AT93112983T patent/ATE165102T1/de active
- 1993-08-13 EP EP93112983A patent/EP0593868B1/en not_active Expired - Lifetime
- 1993-08-16 MW MW7693A patent/MW7693A1/xx unknown
- 1993-08-18 CZ CZ931693A patent/CZ169393A3/cs unknown
- 1993-08-18 HU HU9302366A patent/HUT67013A/hu unknown
- 1993-08-19 ZA ZA936098A patent/ZA936098B/xx unknown
- 1993-08-20 PH PH46719A patent/PH30460A/en unknown
- 1993-08-20 NZ NZ248452A patent/NZ248452A/en unknown
- 1993-08-20 AU AU44780/93A patent/AU668742B2/en not_active Ceased
- 1993-08-20 NZ NZ264872A patent/NZ264872A/en unknown
- 1993-08-20 IL IL106750A patent/IL106750A0/xx unknown
- 1993-08-20 SK SK898-93A patent/SK89893A3/sk unknown
- 1993-08-23 RO RO93-01141A patent/RO112730B1/ro unknown
- 1993-08-23 JP JP5229504A patent/JP2859105B2/ja not_active Expired - Lifetime
- 1993-08-23 BG BG98067A patent/BG98067A/xx unknown
- 1993-08-24 MY MYPI93001695A patent/MY131445A/en unknown
- 1993-08-24 UY UY23635A patent/UY23635A1/es unknown
- 1993-08-25 KR KR1019930016550A patent/KR100295520B1/ko not_active IP Right Cessation
- 1993-08-25 BR BR9303469A patent/BR9303469A/pt not_active Application Discontinuation
- 1993-08-25 CN CNB971054339A patent/CN1183112C/zh not_active Expired - Lifetime
- 1993-08-25 CN CN93116479A patent/CN1039015C/zh not_active Expired - Lifetime
- 1993-08-25 FI FI933740A patent/FI109765B/fi not_active IP Right Cessation
- 1993-08-25 YU YU56693A patent/YU56693A/sh unknown
- 1993-08-25 LV LVP-93-1040A patent/LV10907B/en unknown
- 1993-08-25 MX MX9305146A patent/MX9305146A/es active IP Right Grant
- 1993-08-25 NO NO933028A patent/NO933028D0/no unknown
- 1993-08-25 PL PL93300194A patent/PL300194A1/xx unknown
- 1993-08-25 LT LTIP888A patent/LT3174B/lt not_active IP Right Cessation
- 1993-08-25 IS IS4067A patent/IS4067A/is unknown
- 1993-08-26 ZW ZW11193A patent/ZW11193A1/xx unknown
- 1993-08-26 OA OA60405A patent/OA09850A/fr unknown
1994
- 1994-11-22 EE EE9400151A patent/EE9400151A/xx unknown
1997
- 1997-05-23 CN CNB971054347A patent/CN1155618C/zh not_active Expired - Lifetime

Also Published As

Publication number	Publication date
ZA936098B (en)	1994-03-01
IS4067A (is)	1994-02-27
EE9400151A (et)	1996-02-15
ES2116376T3 (es)	1998-07-16
MY131445A (en)	2007-08-30
DE69317979D1 (de)	1998-05-20
JPH06192300A (ja)	1994-07-12
BR9303469A (pt)	1994-03-22
KR100295520B1 (ko)	2001-09-17
RO112730B1 (ro)	1997-12-30
PH30460A (en)	1997-05-28
AU668742B2 (en)	1996-05-16
CN1173500A (zh)	1998-02-18
HRP931094A2 (en)	1997-06-30
CA2103829C (en)	2003-04-08
NZ264872A (en)	1996-01-26
MW7693A1 (en)	1994-06-08
ZW11193A1 (en)	1994-03-23
CA2103829A1 (en)	1994-02-27
LTIP888A (lt)	1994-08-25
FI933740A (fi)	1994-02-27
CN1211578A (zh)	1999-03-24
LV10907A (lv)	1995-12-20
KR940003969A (ko)	1994-03-14
CN1088936A (zh)	1994-07-06
OA09850A (fr)	1994-08-15
LT3174B (en)	1995-02-27
JP2859105B2 (ja)	1999-02-17
AU4478093A (en)	1994-03-03
CN1155618C (zh)	2004-06-30
SK89893A3 (en)	1994-04-06
HUT67013A (en)	1995-01-30
HU9302366D0 (en)	1993-11-29
EP0593868B1 (en)	1998-04-15
NZ248452A (en)	1995-12-21
SI9300423A (en)	1994-03-31
CZ169393A3 (en)	1994-04-13
DK0593868T3 (da)	1999-02-08
NO933028D0 (no)	1993-08-25
ATE165102T1 (de)	1998-05-15
US5382657A (en)	1995-01-17
BG98067A (en)	1994-12-02
UY23635A1 (es)	1994-03-01
FI933740A0 (fi)	1993-08-25
DE69317979T2 (de)	1998-08-20
MX9305146A (es)	1994-03-31
CN1039015C (zh)	1998-07-08
YU56693A (sh)	1997-01-08
PL300194A1 (en)	1994-04-05
IL106750A0 (en)	1993-12-08
CN1183112C (zh)	2005-01-05
FI109765B (fi)	2002-10-15
EP0593868A1 (en)	1994-04-27

Publication	Publication Date	Title
LV10907B (en)	1996-04-20	Peg/protein derivatives of interferon
CA2063886C (en)	2002-08-20	Polyethylene protein conjugates
US7504477B2 (en)	2009-03-17	Polyalkylene glycol acid additives
US6638500B1 (en)	2003-10-28	Polyol-IFN-βconjugates modified at Cys-17 and composition containing same
PL186949B1 (pl)	2004-04-30	Fizjologicznie czynny koniugat PEG-IFN-alfa, sposób jego wytwarzania oraz zawierające go kompozycjefarmaceutyczne
MXPA04006855A (es)	2005-04-19	Compuestos de polimeros de polialquileno y usos de los mismos.
MX2008014358A (es)	2008-11-24	Conjugado de polietilenglicol-interferon alfa.
KR100480432B1 (ko)	2005-04-06	Ｇ-ｃｓｆ와 폴리에틸렌글리콜 유도체의 배합체
MXPA00010223A (en)	2001-07-31	Polyol-ifn-beta conjugates
KR20030045416A (ko)	2003-06-11	에리트로포이에틴과 폴리에틸렌글리콜 유도체의 배합체